A case-control of patients with COVID-19 to explore the association of previous hospitalisation use of medication on the mortality of COVID-19 disease: a propensity score matching analysis
Author
Monserrat Villatoro, Jaime; Mejía-Abril, Gina; Díaz García, Lucía; Zubiaur Precioso, Pablo; Jiménez González, María; Fernandez Jimenez, Guillermo; Cancio, Inés; Arribas López, José Ramón; Suárez Fernández, M. Carmen; Mingorance, Jesús; García Rodríguez, Julio; Villagrasa Ferrer, José Ramón; Carcas Sansuán, Antonio Javier; Frías Iniesta, Jesús A.; Abad Santos, Francisco; Borobia Pérez, Alberto M.; Ramírez García, ElenaEntity
UAM. Departamento de Medicina; UAM. Departamento de Medicina Preventiva y Salud Pública y Microbiología; UAM. Departamento de Farmacología y TerapéuticaPublisher
MDPI AGDate
2022-01-08Citation
10.3390/ph15010078
Pharmaceuticals 15.1 (2022): 78
ISSN
1424-8247 (online)DOI
10.3390/ph15010078Editor's Version
https://doi.org/10.3390/ph15010078Subjects
coronavirus disease 2019 (COVID-19); hospitalisation; mortality; previous medication; propensity score matching analysis; risk factor; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); MedicinaRights
© 2022 by the authorsAbstract
Data from several cohorts of coronavirus disease 2019 (COVID-19) suggest that the most common comorbidities for severe COVID-19 disease are the elderly, high blood pressure, and diabetes; however, it is not currently known whether the previous use of certain drugs help or hinder recovery. This study aims to explore the association of previous hospitalisation use of medication on the mortality of COVID-19 disease. A retrospective case-control from two hospitals in Madrid, Spain, included all patients aged 18 years or above hospitalised with a diagnosis of COVID-19. A Propensity Score matching (PSM) analysis was performed. Confounding variables were considered to be age, sex, and the number of comorbidities. Finally, 3712 patients were included. Of these, 687 (18.5%) patients died (cases). The 22,446 medicine trademarks used previous to admission were classified according to the ATC, obtaining 689 final drugs; all of them were included in PSM analysis. Eleven drugs displayed a reduction in mortality: azithromycin, bemiparine, budesonide-formoterol fumarate, cefuroxime, colchicine, enoxaparin, ipratropium bromide, loratadine, mepyramine theophylline acetate, oral rehydration salts, and salbutamol sulphate. Eight final drugs displayed an increase in mortality: acetylsalicylic acid, digoxin, folic acid, mirtazapine, linagliptin, enalapril, atorvastatin, and allopurinol. Medication associated with survival (anticoagulants, antihistamines, azithromycin, bronchodilators, cefuroxime, colchicine, and inhaled corticosteroids) may be candidates for future clinical trials. Drugs associated with mortality show an interaction with the underlying conditions
Files in this item
Google Scholar:Monserrat Villatoro, Jaime
-
Mejía-Abril, Gina
-
Díaz García, Lucía
-
Zubiaur Precioso, Pablo
-
Jiménez González, María
-
Fernandez Jimenez, Guillermo
-
Cancio, Inés
-
Arribas López, José Ramón
-
Suárez Fernández, M. Carmen
-
Mingorance, Jesús
-
García Rodríguez, Julio
-
Villagrasa Ferrer, José Ramón
-
Carcas Sansuán, Antonio Javier
-
Frías Iniesta, Jesús A.
-
Abad Santos, Francisco
-
Borobia Pérez, Alberto M.
-
Ramírez García, Elena
This item appears in the following Collection(s)
Related items
Showing items related by title, author, creator and subject.
-
A cohort of patients with COVID-19 in a major teaching hospital in Europe
Borobia Pérez, Alberto M.; Carcas Sansuán, Antonio Javier; Arnalich Fernández, Francisco; Alvarez Sala, Rodolfo; Quintana Díaz, Manuel; García Rodríguez, Julio; Ramírez García, Elena; Reinoso Barbero, Francisco; Mingorance, Jesús; Prados Sánchez, Concepción; Ríos Blanco, Juan José; Frías Iniesta, Jesús A.; Arribas, José R.
2020-06-04